Advanced glycation end products promote osteoporosis by inducing ferroptosis in osteoblasts

被引:70
|
作者
Ge, Weiwei [1 ]
Jie, Jian [2 ]
Yao, Jie [3 ]
Li, Wei [1 ]
Cheng, Yahui [1 ]
Lu, Wenjuan [3 ]
机构
[1] Nanjing Pukou Dist Cent Hosp, Jiangsu Peoples Hosp, Dept Radiol, Pukou Branch, Nanjing 210018, Jiangsu, Peoples R China
[2] Nanjing Pukou Dist Cent Hosp, Jiangsu Peoples Hosp, Dept Orthoped, Pukou Branch, Nanjing 210018, Jiangsu, Peoples R China
[3] Nanjing Municipal Govt Hosp, Nanjing Cent Hosp, Dept Radiol, 116 Chengxian St, Nanjing 210018, Jiangsu, Peoples R China
关键词
advanced glycation end products; ferroptosis; osteoblast; osteoporosis; type-2 diabetes mellitus; EXPRESSION; FRACTURE; KINASE; CELLS; WOMEN; AGES;
D O I
10.3892/mmr.2022.12656
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Advanced glycation end products (AGEs) have been widely reported to play an important role in osteoporosis (OP), particularly in diabetes-related OP. The aim of the present study was to investigate the effect of AGEs on osteoblast function and the underlying mechanisms. The level of bone mineral density (BMD), serum AGEs and fasting blood glucose (FBG) was measured in patients with OP and healthy individuals, and the correlation between AGE levels and BMD or FBG was then analyzed. For the in vitro experiments, the hFOB1.19 osteoblast cell line was cultured in medium containing AGEs and serum from healthy individuals or patients with OP, and with or without type-2 diabetes mellitus (T2DM). Cell proliferation, differentiation, mineralization, apoptosis and ferroptosis were evaluated using Cell Counting Kit-8 and alkaline phosphatase (ALP) assays, Alizarin red and TUNEL staining, iron indicator, lipid peroxidation tests and western blot analysis, respectively. In a separate set of experiments, the ferroptosis inhibitor, deferoxamine (DFO), was also added to the culture medium of cells treated with AGEs and serum from patients with OP and T2DM. The results demonstrated that patients with OP had a higher level of serum AGEs and FBG compared with that in healthy individuals. The level of serum AGEs in patients with OP was negatively correlated with BMD, but was positively correlated with FBG. In addition, AGEs and serum from patients with OP markedly inhibited hFOB1.19 cell proliferation, ALP production and mineralized nodule formation. Apoptosis and ferroptosis were significantly promoted by AGEs and serum from patients with OP. Moreover, serum from OP patients with T2DM caused stronger effect than that from OP patients with normal FBG. However, DFO reversed the effects induced by AGEs and serum from patients with OP and T2DM on hFOB1.19 cells. Collectively, AGEs could disrupt the functions of osteoblasts by inducing cell ferroptosis, thus contributing to OP.
引用
收藏
页数:9
相关论文
共 50 条
  • [1] Advanced glycation end products affect growth and function of osteoblasts
    Franke, S.
    Ruester, C.
    Pester, J.
    Hofmann, G.
    Oelzner, P.
    Wolf, G.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2011, 29 (04) : 650 - 660
  • [2] Effects of Advanced Glycation End Products on Differentiation and Function of Osteoblasts and Osteoclasts
    Park, So Young
    Choi, Kyoung Hee
    Jun, Ji Eun
    Chung, Ho Yeon
    JOURNAL OF KOREAN MEDICAL SCIENCE, 2021, 36 (37)
  • [3] Advanced Glycation End Products Promote Heart Failure Through Inducing the Immune Maturation of Dendritic Cells
    Cao, Weiwei
    Chen, Jianwen
    Chen, Yanfang
    Chen, Xi
    Liu, Peiqing
    APPLIED BIOCHEMISTRY AND BIOTECHNOLOGY, 2014, 172 (08) : 4062 - 4077
  • [4] Advanced Glycation End Products Promote Heart Failure Through Inducing the Immune Maturation of Dendritic Cells
    Weiwei Cao
    Jianwen Chen
    Yanfang Chen
    Xi Chen
    Peiqing Liu
    Applied Biochemistry and Biotechnology, 2014, 172 : 4062 - 4077
  • [5] Role of Advanced Glycation End Products (AGEs) in Osteoporosis in Diabetes
    Yamagishi, Sho-ichi
    CURRENT DRUG TARGETS, 2011, 12 (14) : 2096 - 2102
  • [6] Serum levels of advanced glycation end-products (AGEs) in osteoporosis
    Lehmann, G
    Franke, S
    Wiegand, R
    Hein, G
    ARTHRITIS AND RHEUMATISM, 2001, 44 (09): : S259 - S259
  • [7] Advanced Glycation End Products Play Adverse Proinflammatory Activities in Osteoporosis
    Sanguineti, Roberta
    Puddu, Alessandra
    Mach, Francois
    Montecucco, Fabrizio
    Viviani, Giorgio Luciano
    MEDIATORS OF INFLAMMATION, 2014, 2014
  • [8] Advanced glycation end products and receptor for advanced glycation end products in AA amyloidosis
    Röcken, C
    Kientsch-Engel, R
    Mansfeld, S
    Stix, B
    Stubenrauch, K
    Weigle, B
    Bühling, F
    Schwan, M
    Saeger, W
    AMERICAN JOURNAL OF PATHOLOGY, 2003, 162 (04): : 1213 - 1220
  • [9] Advanced Glycation End Products
    Thomas, Merlin C.
    DIABETES AND THE KIDNEY, 2011, 170 : 66 - 74
  • [10] Possible participation of advanced glycation end products in the pathogenesis of osteoporosis in diabetic patients
    Yamagishi, S
    Nakamura, K
    Inoue, H
    MEDICAL HYPOTHESES, 2005, 65 (06) : 1013 - 1015